UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE

Inflammatory bowel diseases, 2012-01, Vol.18 (1), p.1-9

2012

Volltextzugriff (PDF)

Stopping Biologics in IBD-What Is the Evidence?

Inflammatory bowel diseases, 2018-03, Vol.24 (4), p.725-731

Louis, Edouard

2018

Volltextzugriff (PDF)

Multicenter randomized‐controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo‐caecal resection

Inflammatory bowel diseases, 2007-02, Vol.13 (2), p.135-142

2007

Volltextzugriff (PDF)

Immunosuppressant combined with infliximab in Crohn's Disease: For 6 months, for 2 years, or forever?

Inflammatory bowel diseases, 2011-03, Vol.17 (3), p.858-859

Louis, Edouard

2011

Volltextzugriff (PDF)

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

Inflammatory bowel diseases, 2019-01, Vol.25 (1), p.156-162

2019

Volltextzugriff (PDF)

Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease

Inflammatory bowel diseases, 2014-06, Vol.20 (6), p.978-986

2014

Volltextzugriff (PDF)

In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab

Inflammatory bowel diseases, 2024-02, Vol.30 (2), p.240-246

2024

Volltextzugriff (PDF)

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases

Inflammatory bowel diseases, 2017-03, Vol.23 (3), p.333-340

2017

Volltextzugriff (PDF)

Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn's Disease

Inflammatory bowel diseases, 2024-09

2024

Volltextzugriff (PDF)

Serum adalimumab concentration and clinical remission in patients with Crohn's disease

Inflammatory bowel diseases, 2013-05, Vol.19 (6), p.1112-1122

2013

Volltextzugriff (PDF)

Development of the Crohn's disease digestive damage score, the Lémann score

Inflammatory bowel diseases, 2011-06, Vol.17 (6), p.1415-1422

2011

Volltextzugriff (PDF)

Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study

Inflammatory bowel diseases, 2022-07, Vol.28 (7), p.1034-1044

2022

Volltextzugriff (PDF)

Multicenter randomized-control led clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection

2007-02

Volltextzugriff (PDF)

Bariatric Surgery in Patients With Inflammatory Bowel Disease: A Case-Control Study from the GETAID

Inflammatory bowel diseases, 2022-08, Vol.28 (8), p.1198-1206

2022

Volltextzugriff (PDF)

Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases

Inflammatory bowel diseases, 2022-02, Vol.28 (2), p.208-217

2022

Volltextzugriff (PDF)

Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy

Inflammatory bowel diseases, 2013-09, Vol.19 (10), p.2111-2117

2013

Volltextzugriff (PDF)

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study

Inflammatory bowel diseases, 2018-04, Vol.24 (5), p.1099-1105

2018

Volltextzugriff (PDF)

Evolving definitions of remission in Crohn's disease

Inflammatory bowel diseases, 2013-07, Vol.19 (8), p.1645-1653

2013

Volltextzugriff (PDF)

Assessment of endoscopic activity lndex and biological lnflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level

2007-09

Volltextzugriff (PDF)

Therapeutic Targeting of Specific Populations (Pharmacogenetics)

Inflammatory bowel diseases, 2006-04, Vol.12, p.S15

Louis, Edouard

2006

Volltextzugriff (PDF)

Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level

Inflammatory bowel diseases, 2007-09, Vol.13 (9), p.1100-1105

2007

Volltextzugriff (PDF)

P037 LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) MONOCLONAL ANTIBODY SHP647 IN CROHN’S DISEASE: THE OPERA II STUDY

Inflammatory bowel diseases, 2019-02, Vol.25 (Supplement_1), p.S18-S19

2019

Volltextzugriff (PDF)

Genome-Wide Copy Number Variation Scan Identifies Complement Component C4 as Novel Susceptibility Gene for Crohn's Disease

Inflammatory bowel diseases, 2016-03, Vol.22 (3), p.505-515

2016

Volltextzugriff (PDF)

Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 Years

Inflammatory bowel diseases, 2016-12, Vol.22 (12), p.2924-2932

2016

Volltextzugriff (PDF)

Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohn's Disease Registry (BELCRO)

Inflammatory bowel diseases, 2017-09, Vol.23 (9), p.1584-1591

2017

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Aktive Filter

KollektionOxford journals

KollektionWiley Online Library Journals Frontfile Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(42)
Berichte
(1)

Sprache

Englisch
(43)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE

Stopping Biologics in IBD-What Is the Evidence?

Multicenter randomized‐controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo‐caecal resection

Immunosuppressant combined with infliximab in Crohn's Disease: For 6 months, for 2 years, or forever?

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease

In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases

Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn's Disease

Serum adalimumab concentration and clinical remission in patients with Crohn's disease

Development of the Crohn's disease digestive damage score, the Lémann score

Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study

Multicenter randomized-control led clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection

Bariatric Surgery in Patients With Inflammatory Bowel Disease: A Case-Control Study from the GETAID

Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases

Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study

Evolving definitions of remission in Crohn's disease

Assessment of endoscopic activity lndex and biological lnflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level

Therapeutic Targeting of Specific Populations (Pharmacogenetics)

Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level

P037 LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) MONOCLONAL ANTIBODY SHP647 IN CROHN’S DISEASE: THE OPERA II STUDY

Genome-Wide Copy Number Variation Scan Identifies Complement Component C4 as Novel Susceptibility Gene for Crohn's Disease

Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 Years

Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohn's Disease Registry (BELCRO)

Aktive Filter

Suchergebnisse filtern